Author:
Mignogna Chiara,Staibano Stefania,Altieri Vincenzo,De Rosa Gaetano,Pannone Giuseppe,Santoro Angela,Zamparese Rosanna,D'Armiento Massimino,Rocchetti Romualdo,Mezza Ernesto,Nasti Mario,Strazzullo Viviana,Montanaro Vittorino,Mascolo Massimo,Bufo Pantaleo
Abstract
Abstract
Background
A large number of renal cancer patients shows poor or partial response to chemotherapy and the mechanisms have not been still understood. Multi-drug resistance is the principal mechanism by which many cancers develop resistance to chemotherapic drugs. The role of the multi-drug resistant transporter (MDR-1/P-glycoprotein), the gene product of MDR-1, and that one of the so-called multi-drug resistance associated protein (MRP), two energy-dependent efflux pumps, are commonly known to confer drug resistance.
We studied MDR-1 expression in selected cases of renal cell carcinoma (RCC), clear cell type, with long-term follow-up, in order to establish its prognostic role and its possible contribution in the choice of post-surgical therapy.
Methods
MDR-1 has been studied by standard LSAB-HRP immunohistochemical technique, in paraffin embedded RCC samples. Protein expression has been compared to clinical and histopathological data and to disease specific survival of RCC patients, by Kaplan-Meier curve and Cox multivariate regression analyses.
Results
Two groups of RCCs were obtained by esteeming MDR-1 expression and disease specific survival (obtained with Kaplan-Meier curve and Cox multivariate regression analyses): the first one presents low or absent MDR-1 expression and good survival; the second one is characterized by high MDR-1 expression and significant poor outcome (p < 0.05). Afterwards, we have found disease specific survival, adjusted for stages and independent of therapy: this difference of survival rates was statistically significant (p < 0.05). Stage adjusted disease specific survival rate, according to MDR-1 expression and therapy in patients affected by RCC in early stage (stage I), has revealed that the group of patients with high MDR-1 expression and without adjuvant therapy showed poor survival (p < 0.05). Cox multivariate regression analysis has confirmed that, in our cohort of RCC (clear cell type) patients, the strong association between MDR-1 and worse outcome is independent not only of the adjuvant therapy, but also of the other prognostic parameters (p < 0.05).
Conclusion
In our opinion, the results of this study well prove the relationship between MDR-1 expression and worse clinical prognosis in RCC, because MDR-1 over-expressing RCCs can be considered a group of tumours with a more aggressive behavior. This finding outlines a possible role of MDR-1 as prognostic factor, dependent and independent of multidrug resistance. These results could be useful to predict cancer evolution and to choose the appropriate treatment: this is another step that can stimulate further promising and interesting investigations on broader study population.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference44 articles.
1. Jemal A, Murray T, Ward E: Cancer Statistics. CA Cancer J Clin. 2005, 55: 10-30.
2. Vogelzang NJ, Stadler WM: Kidney cancer. Lancet. 1998, 352: 1691-6. 10.1016/S0140-6736(98)01041-1.
3. Stenzl A, deKernion JB: Pathology, biology and clinical staging of renal cell carcinoma. Semin Oncol Suppl. 1989, 16: 3-15.
4. Buzaid AC, Todd MB: Therapeutic options in renal cell carcinoma. Semin Oncol. 1989, 16 (suppl 6): 12-16.
5. Mrstik C, Salamon J, Weber R: Microscopic venous infiltration as predictor of relapse in renal cell carcinoma. J Urol. 1992, 148: 271-74.
Cited by
44 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献